Drugs / huJCAR014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03103971 | Nov 2017 → Mar 2023 | B-cell acute lymphoblastic leukemia, adult acute lymphoblastic leukemia, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huJCAR014 | “This phase I trial studies the side effects of huJCAR014 in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia.” NCT03103971 ↗ |
| Action | Deplete | “may specifically kill cancer cells that have a molecule CD19 on their surfaces.” NCT03103971 ↗ |
| Modality | Cell therapy | “huJCAR014 CAR-T cells are made in the laboratory by genetically modifying a patient's T cells” NCT03103971 ↗ |
| Route | Intravenous | “Given IV” NCT03103971 ↗ |